Uygun Vedat, Russo Roberta, Karasu Gülsün, Daloğlu Hayriye, Iolascon Achille, Yeşilipek Akif
Department of Pediatric Bone Marrow Transplantation Unit, MedicalPark Antalya Hospital, Antalya, Turkey.
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II and CEINGE-Advanced Biotechnologies, Naples, Italy.
J Pediatr Hematol Oncol. 2020 Aug;42(6):e507-e510. doi: 10.1097/MPH.0000000000001612.
Currently, there is no guideline for the treatment of patients with congenital dyserythropoietic anemia (CDA) type II. One approach is to follow-up patients with transfusions, on the basis of individually determined target hemoglobin levels, and iron chelation according to the thalassemia guidelines. In some transfusion-dependent CDA II patients, splenectomy reduces the number of transfusions; however, the only known curative option for CDA II patients is hematopoietic stem cell transplantation (HSCT). Only a few published case reports of allogeneic HSCT in CDA II patients are available. Here, we review the literature and add our data of a CDA II patient who developed transfusion dependence and was cured with HSCT.
目前,对于II型先天性红细胞生成异常性贫血(CDA)患者尚无治疗指南。一种方法是根据个体确定的目标血红蛋白水平,通过输血对患者进行随访,并按照地中海贫血指南进行铁螯合治疗。在一些依赖输血的CDA II型患者中,脾切除术可减少输血量;然而,CDA II型患者唯一已知的治愈方法是造血干细胞移植(HSCT)。关于CDA II型患者异基因HSCT的已发表病例报告仅有少数几例。在此,我们回顾相关文献,并补充我们关于一名发展为输血依赖并通过HSCT治愈的CDA II型患者的数据。